Jonathan E. Lim - 03 Feb 2025 Form 4 Insider Report for Maze Therapeutics, Inc. (MAZE)

Reporting relationship: Director
Issuer ticker: MAZE
Reported as of: 03 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Feb 2025, 16:37:54 UTC
Prior SEC filing: 30 Jan 2025
Next SEC filing: 23 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Courtney Phillips, as attorney-in-fact

Key filing fact

Jonathan E. Lim filed Form 4 for Maze Therapeutics, Inc. (MAZE) on 04 Feb 2025.

Key facts

This page summarizes Jonathan E. Lim's Form 4 filing for Maze Therapeutics, Inc. (MAZE).
7 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 04 Feb 2025, 16:37.

Change

Previous filing in this sequence was filed on 30 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MAZE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +37,724
Change %
Price
Shares after: 37,724
Date: 03 Feb 2025
Ownership: City Hill, LLC
Footnotes: F1, F2

MAZE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +270,232
Change %: +716%
Price
Shares after: 307,956
Date: 03 Feb 2025
Ownership: City Hill, LLC
Footnotes: F2, F3

MAZE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 20,744
Date: 03 Feb 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MAZE transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value
Shares: -363,703
Change %: -100%
Price
Shares after: 0
Date: 03 Feb 2025
Ownership: City Hill, LLC
Underlying class: Common Stock
Underlying amount: 37,724
Exercise price
Footnotes: F1, F2

MAZE transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -2,231,381
Change %: -100%
Price
Shares after: 0
Date: 03 Feb 2025
Ownership: City Hill, LLC
Underlying class: Common Stock
Underlying amount: 270,232
Exercise price
Footnotes: F2, F3

MAZE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +5,704
Change %
Price
Shares after: 5,704
Date: 09 Dec 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,704
Exercise price: $10.42
Footnotes: F4, F5, F6

MAZE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -5,704
Change %: -100%
Price
Shares after: 0
Date: 09 Dec 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,704
Exercise price: $17.74
Footnotes: F4, F5, F6

MAZE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +9,086
Change %
Price: $0.000000
Shares after: 9,086
Date: 09 Dec 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,086
Exercise price: $10.42
Footnotes: F4, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date.

Footnote F2

These securities are directly held by City Hill, LLC, of which the reporting person is the managing partner.

Footnote F3

Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date.

Footnote F4

This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and exercise prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025.

Footnote F5

The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Footnote F6

This option, which was first granted on March 9, 2023, was canceled and exchanged for a new option having a lower exercise price in connection with an option repricing approved by the Issuer's Board of Directors on December 9, 2024. All terms of the option remained unchanged other than the exercise price.

Footnote F7

The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.